Lentiviral vector-mediated siRNA knockdown of c-MYC: Cell growth inhibition and cell cycle arrest at G2/M phase in Jijoye cells

Biochemical Genetics

Volumn 51, Issue 7-8, 2013, Pages 603-617

  Song, Aiqin ^a   Ye, Junli ^a   Zhang, Kunpeng ^a   Sun, Lirong ^a   Zhao, Yanxia ^a   Yu, Hongsheng ^a  

^a QINGDAO UNIVERSITY MEDICAL COLLEGE   (China)

Author keywords

c MYC; Cell cycle; Jijoye cells; Lentiviral vector; siRNA

Indexed keywords

CASPASE 3; CYCLIN B; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE INHIBITOR 1; DNA FRAGMENT; LENTIVIRUS VECTOR; MESSENGER RNA; MYC PROTEIN; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; BURKITT LYMPHOMA; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DNA FRAGMENTATION; DOWN REGULATION; DRUG TARGETING; EMBRYO; ENZYME ACTIVATION; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOMA CELL LINE; PROTEIN EXPRESSION;

APOPTOSIS; CASPASE 3; CELL CYCLE; CELL CYCLE CHECKPOINTS; CELL DIVISION; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; G2 PHASE; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; GENETIC VECTORS; HUMANS; LENTIVIRUS; PROTO-ONCOGENE PROTEINS C-MYC; RNA, SMALL INTERFERING;

EID: 84880718260     PISSN: 00062928     EISSN: 15734927     Source Type: Journal    
DOI: 10.1007/s10528-013-9590-0     Document Type: Article

References (43)

1. Aravin A, Tuschl T (2005) Identification and characterization of small RNAs involved in RNA silencing. FEBS Lett 579(26):5830-5840
2. Aukema SM, Siebert R, Schuuring E, van Imhoff GW, Kluin-Nelemans HC, Boerma EJ, Kluin PM (2011) Double-hit B-cell lymphomas. Blood 117(8):2319-2331
3. Baluchamy S, Rajabi HN, Thimmapaya R, Navaraj A, Thimmapaya B (2003) Repression of c-MYC and inhibition of G1 exit in cells conditionally overexpressing p300 that is not dependent on its histone acetyltransferase activity. Proc Natl Acad Sci USA 100(16):9524-9529
4. Blum KA, Lozanski G, Byrd JC (2004) Adult Burkitt leukemia and lymphoma. Blood 104(10):3009-3020
5. Bosher JM, Labouesse M (2000) RNA interference: genetic wand and genetic watchdog. Nat Cell Biol 2(2):E31-E36
6. Busch K, Keller T, Fuchs U, Yeh RF, Harbott J, Klose I, Wiemels J, Novosel A, Reiter A, Borkhardt A (2007) Identification of two distinct MYC breakpoint clusters and their association with various IGH breakpoint regions in the t(8;14) translocations in sporadic Burkitt-lymphoma. Leukemia 21(8):1739-1751
7. Cao X, Bennett RL, May WS (2008) c-MYC and caspase-2 are involved in activating Bax during cytotoxic drug-induced apoptosis. J Biol Chem 283(21):14490-14496
8. Dang CV (2012) MYC on the path to cancer. Cell 30-149(1):22-35
9. Dang CV, Lewis BC (1997) Role of oncogenic transcription factor c-MYC in cell cycle regulation, apoptosis and metabolism. J Biomed Sci 4(6):269-278
10. Dropulić B (2011) Lentiviral vectors: their molecular design, safety, and use in laboratory and preclinical research. Hum Gene Ther 22(6):649-657
11. Gartel AL, Shchors K (2003) Mechanisms of c-MYC-mediated transcriptional repression of growth arrest genes. Exp Cell Res 283(1):17-21
12. Gustafson WC, Weiss WA (2010) Myc proteins as therapeutic targets. Oncogene 29(9):1249-1259
13. Herkert B, Eilers M (2010) Transcriptional repression: the dark side of myc. Genes Cancer 1(6):580-586
14. Hoffman B, Liebermann DA (2008) Apoptotic signaling by c-MYC. Oncogene 27(50):6462-6472
15. Hong J, Zhao Y, Huang W (2006) Blocking c-MYC and stat3 by E. coli expressed and enzyme digested siRNA in mouse melanoma. Biochem Biophys Res Commun 348(2):600-605
16. Hotti A, Järvinen K, Siivola P, Hölttä E (2000) Caspases and mitochondria in c-Myc-induced apoptosis: identification of ATM as a new target of caspases. Oncogene 19(19):2354-2362
17. Joos S, Falk MH, Lichter P, Haluska FG, Henglein B, Lenoir GM, Bornkamm GW (1992) Variable breakpoints in Burkitt lymphoma cells with chromosomal t(8;14) translocation separate c-MYC and the IgH locus up to several hundred kb. Hum Mol Genet 1:625-632
18. Jung P, Hermeking H (2009) The c-MYC-AP4-p21 cascade. Cell Cycle 8(7):982-989
19. Kabilova TO, Vladimirova AV, Chernolovskaya EL, Vlassov VV (2006) Arrest of cancer cell proliferation by dsRNAs. Ann NY Acad Sci 1091:425-436
20. Kangas A, Nicholson DW, Hölttä E (1998) Involvement of CPP32/Caspase-3 in c-Myc-induced apoptosis. Oncogene 16(3):387-398
21. Klapproth K, Wirth T (2010) Advances in the understanding of MYC-induced lymphomagenesis. Br J Haematol 149(4):484-497
22. Kuttler F, Mai S (2006) c-MYC, genomic instability and disease. Genome Dyn 1:171-190
23. Lin CP, Liu JD, Chow JM, Liu CR, Liu HE (2007) Small-molecule c-MYC inhibitor, 10058-F4, inhibits proliferation, downregulates human telomerase reverse transcriptase and enhances chemosensitivity in human hepatocellular carcinoma cells. Anticancer Drugs 18(2):161-170
24. TΔΔC method. Methods 25:402-408
25. Llano M, Gaznick N, Poeschla EM (2009) Rapid, controlled and intensive lentiviral vector-based RNAi. Methods Mol Biol 485:257-270
26. Magrath I (1990) The pathogenesis of Burkitt's lymphoma. Adv Cancer Res 55:133-270
27. Morrish F, Neretti N, Sedivy JM, Hockenbery DM (2008) The oncogene c-MYC coordinates regulation of metabolic networks to enable rapid cell cycle entry. Cell Cycle 7(8):1054-1066
28. Morrish F, Isern N, Sadilek M, Jeffrey M, Hockenbery DM (2009) c-MYC activates multiple metabolic networks to generate substrates for cell-cycle entry. Oncogene 28(27):2485-2491
29. Nigris F, Balestrieri ML, Napoli C (2006) Targeting c-MYC, Ras and IGF cascade to treat cancer and vascular disorders. Cell Cycle 5(15):1621-1628
30. Obaya AJ, Kotenko I, Cole MD, Sedivy JM (2002) The proto-oncogene c-MYC acts through the cyclin-dependent kinase (Cdk) inhibitor P21(Kip1) to facilitate the activation of Cdk4/6 and early G(1) phase progression. J Biol Chem 277(34):31263-31269
31. Pajic A, Spitkovsky D, Christoph B, Kempkes B, Schuhmacher M, Staege MS, Brielmeier M, Ellwart J, Kohlhuber F, Bornkamm GW, Polack A, Eick D (2000) Cell cycle activation by c-MYC in a Burkitt lymphoma model cell line. Int J Cancer 87(6):787-793
32. Peterson CW, Ayer DE (2011) An extended Myc network contributes to glucose homeostasis in cancer and diabetes. Front Biosci 17:2206-2223
33. Radziszewska A, Schroer SA, Choi D, Tajmir P, Radulovich N, Ho JC, Wang L, Liadis N, Hakem R, Tsao MS, Penn LZ, Evan GI, Woo M (2009) Absence of caspase-3 protects pancreatic β-cells from c-Myc-induced apoptosis without leading to tumor formation. J Biol Chem 284(16):10947-10956
34. Salaverria I, Siebert R (2011) The gray zone between Burkitt's lymphoma and diffuse large B-cell lymphoma from a genetics perspective. J Clin Oncol 29(14):1835-1843
35. Schiffer CA (2001) Treatment of high-grade lymphoid malignancies in adults. Semin Hematol 38(4 Suppl 10):22-26
36. Schlee M, Schuhmacher M, Hölzel M, Laux G, Bornkamm GW (2007) c-MYC impairs immunogenicity of human B cells. Adv Cancer Res 97:167-188
37. Slack GW, Gascoyne RD (2011) MYC and aggressive B-cell lymphomas. Adv Anat Pathol 18(3):219-228
38. Sobolewski C, Cerella C, Dicato M, Diederich M (2011) Cox-2 inhibitors induce early c-MYC downregulation and lead to expression of differentiation markers in leukemia cells. Cell Cycle 10(17):2978-2993
39. Steidl C, Gascoyne RD (2011) The molecular pathogenesis of primary mediastinal large B-cell lymphoma. Blood 118(10):2659-2669
40. Tomita N (2011) BCL2 and MYC dual-hit lymphoma/leukemia. J Clin Exp Hematop 51(1):7-12
41. Vermeulen K, Berneman ZN, Van Bockstaele DR (2003) Cell cycle and apoptosis. Cell Prolif 36(3):165-175
42. Yap CS, Peterson AL, Castellani G, Sedivy JM, Neretti N (2011) Kinetic profiling of the c-MYC transcriptome and bioinformatic analysis of repressed gene promoters. Cell Cycle 10(13):2184-2196
43. Zimonjic DB, Keck-Waggoner C, Popescu NC (2001) Novel genomic imbalances and chromosome translocations involving c-MYC gene in Burkitt's lymphoma. Leukemia 15(10):1582-1588